Tvardi Therapeutics Inc (TVRD) financials
Tvardi Therapeutics revenue and earnings by year
Tvardi Therapeutics's revenue was $21.0 million in the fiscal year to December 31, 2023, down 49.9% from the year before. Net income was -$119 million, -565.2% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 119.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 8 fiscal years
| Fiscal year to | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 42 | 23 | 135 | 20 | 13 | 1 | 0 |
| Revenue growth | -49.9% | 81.8% | -83.0% | 579.3% | 47.6% | 1378.5% | 959.3% | — |
| Gross profit | 15 | 35 | — | — | — | — | — | — |
| Gross margin | 70.6% | 82.6% | — | — | — | — | — | — |
| Operating income | -121 | -88 | -89 | 5 | -112 | -77 | -59 | -58 |
| Operating margin | -579.4% | -209.1% | -386.8% | 4.0% | -561.6% | -574.5% | -6529.6% | -67907.0% |
| Net income | -119 | -85 | -88 | 8 | -106 | -74 | -58 | -57 |
| Net margin | -565.2% | -204.2% | -384.1% | 6.2% | -534.9% | -549.5% | -6380.4% | -66604.7% |
| Diluted EPS | -$78.78 | -$57.36 | -$62.64 | — | — | — | — | — |
| Free cash flow | -94 | -79 | -60 | -6 | -109 | -22 | -55 | -48 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TVRD in Markets.
See also: TVRD returns
No forecast, no recommendation. This page describes Tvardi Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.